E
BIOLASE, Inc.
BIOLQ
$0.0075
-$0.0014-15.73%
E
Sell
2/13/2025Downgrade
BIOLASE, Inc. (BIOLQ) was downgraded to E from E+ on 2/13/2025 due to a decline in the volatility index.
BIOLASE, Inc. (BIOLQ) was downgraded to E from E+ on 2/13/2025 due to a decline in the volatility index.
E
Sell
1/28/2025Upgraded
BIOLASE, Inc. (BIOLQ) was upgraded to E+ from E on 1/28/2025 due to an increase in the volatility index.
BIOLASE, Inc. (BIOLQ) was upgraded to E+ from E on 1/28/2025 due to an increase in the volatility index.
E
Sell
1/7/2025Downgrade
BIOLASE, Inc. (BIOLQ) was downgraded to E from E+ on 1/7/2025 due to a decline in the volatility index and total return index.
BIOLASE, Inc. (BIOLQ) was downgraded to E from E+ on 1/7/2025 due to a decline in the volatility index and total return index.
E
Sell
12/20/2024Upgraded
BIOLASE, Inc. (BIOLQ) was upgraded to E+ from E on 12/20/2024 due to an increase in the volatility index, growth index and total return index. EBIT increased 78.42% from -$3.22M to -$695, and earnings per share increased from -$0.0838 to -$0.0376.
BIOLASE, Inc. (BIOLQ) was upgraded to E+ from E on 12/20/2024 due to an increase in the volatility index, growth index and total return index. EBIT increased 78.42% from -$3.22M to -$695, and earnings per share increased from -$0.0838 to -$0.0376.
E
Sell
10/22/2024Downgrade
BIOLASE, Inc. (BIOLQ) was downgraded to E from E+ on 10/22/2024 due to a decline in the volatility index and total return index.
BIOLASE, Inc. (BIOLQ) was downgraded to E from E+ on 10/22/2024 due to a decline in the volatility index and total return index.
E
Sell
10/7/2024Upgraded
BIOLASE, Inc. (BIOLQ) was upgraded to E+ from E on 10/7/2024 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 87.64% from -$5.94M to -$734, earnings per share increased from -$0.3635 to -$0.0838, and EBIT increased 28.86% from -$4.53M to -$3.22M.
BIOLASE, Inc. (BIOLQ) was upgraded to E+ from E on 10/7/2024 due to a noticeable increase in the growth index, volatility index and total return index. Operating cash flow increased 87.64% from -$5.94M to -$734, earnings per share increased from -$0.3635 to -$0.0838, and EBIT increased 28.86% from -$4.53M to -$3.22M.
E
Sell
5/24/2024Downgrade
BIOLASE, Inc. (BIOL) was downgraded to E from E+ on 5/24/2024 due to a decline in the volatility index, growth index and total return index.
BIOLASE, Inc. (BIOL) was downgraded to E from E+ on 5/24/2024 due to a decline in the volatility index, growth index and total return index.
E
Sell
5/9/2024Upgraded
BIOLASE, Inc. (BIOL) was upgraded to E+ from E on 5/9/2024 due to an increase in the volatility index.
BIOLASE, Inc. (BIOL) was upgraded to E+ from E on 5/9/2024 due to an increase in the volatility index.
E
Sell
4/12/2024Downgrade
BIOLASE, Inc. (BIOL) was downgraded to E from E+ on 4/12/2024 due to a decline in the volatility index.
BIOLASE, Inc. (BIOL) was downgraded to E from E+ on 4/12/2024 due to a decline in the volatility index.
E
Sell
3/27/2024Upgraded
BIOLASE, Inc. (BIOL) was upgraded to E+ from E on 3/27/2024 due to an increase in the volatility index.
BIOLASE, Inc. (BIOL) was upgraded to E+ from E on 3/27/2024 due to an increase in the volatility index.
E
Sell
3/7/2024Downgrade
BIOLASE, Inc. (BIOL) was downgraded to E from E+ on 3/7/2024 due to a decline in the volatility index.
BIOLASE, Inc. (BIOL) was downgraded to E from E+ on 3/7/2024 due to a decline in the volatility index.
E
Sell
2/21/2024Upgraded
BIOLASE, Inc. (BIOL) was upgraded to E+ from E on 2/21/2024 due to an increase in the valuation index and volatility index.
BIOLASE, Inc. (BIOL) was upgraded to E+ from E on 2/21/2024 due to an increase in the valuation index and volatility index.
E
Sell
2/1/2024Downgrade
BIOLASE, Inc. (BIOL) was downgraded to E from E+ on 2/1/2024 due to a large decline in the solvency index, volatility index and valuation index. Debt to equity increased from 2.24 to 45.13, and the quick ratio declined from 0.69 to 0.62.
BIOLASE, Inc. (BIOL) was downgraded to E from E+ on 2/1/2024 due to a large decline in the solvency index, volatility index and valuation index. Debt to equity increased from 2.24 to 45.13, and the quick ratio declined from 0.69 to 0.62.
E
Sell
3/14/2023Downgrade
BIOLASE, Inc. (BIOLQ) was downgraded to E+ from D- on 03/14/2023.
BIOLASE, Inc. (BIOLQ) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/27/2023Downgrade
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 2/27/2023 due to a decline in the volatility index.
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 2/27/2023 due to a decline in the volatility index.
D
Sell
2/9/2023Upgraded
BIOLASE, Inc. (BIOL) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
BIOLASE, Inc. (BIOL) was upgraded to D from E+ on 2/9/2023 due to an increase in the volatility index.
E
Sell
2/8/2023Downgrade
BIOLASE, Inc. (BIOLQ) was downgraded to E+ from D- on 02/08/2023.
BIOLASE, Inc. (BIOLQ) was downgraded to E+ from D- on 02/08/2023.
D
Sell
2/3/2023Downgrade
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 2/3/2023 due to a large decline in the growth index, solvency index and total return index. Debt to equity increased from 0.62 to 0.97, EBIT declined 51.36% from -$5.06M to -$7.65M, and the quick ratio declined from 1.84 to 1.08.
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 2/3/2023 due to a large decline in the growth index, solvency index and total return index. Debt to equity increased from 0.62 to 0.97, EBIT declined 51.36% from -$5.06M to -$7.65M, and the quick ratio declined from 1.84 to 1.08.
D
Sell
5/16/2022Upgraded
BIOLASE, Inc. (BIOL) was upgraded to D from E+ on 5/16/2022 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.8598 to -$0.8107.
BIOLASE, Inc. (BIOL) was upgraded to D from E+ on 5/16/2022 due to a noticeable increase in the growth index and volatility index. Earnings per share increased from -$0.8598 to -$0.8107.
E
Sell
5/13/2022Downgrade
BIOLASE, Inc. (BIOL) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
BIOLASE, Inc. (BIOL) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index and total return index.
D
Sell
5/4/2022Upgraded
BIOLASE, Inc. (BIOL) was upgraded to D from E+ on 5/4/2022 due to a noticeable increase in the valuation index.
BIOLASE, Inc. (BIOL) was upgraded to D from E+ on 5/4/2022 due to a noticeable increase in the valuation index.
E
Sell
5/1/2022Downgrade
BIOLASE, Inc. (BIOL) was downgraded to E+ from D- on 5/1/2022 due to a noticeable decline in the valuation index and volatility index.
BIOLASE, Inc. (BIOL) was downgraded to E+ from D- on 5/1/2022 due to a noticeable decline in the valuation index and volatility index.
D
Sell
4/20/2022Downgrade
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index and solvency index. Debt to equity increased from 0.46 to 0.56, and the quick ratio declined from 2.75 to 2.47.
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 4/20/2022 due to a major decline in the total return index and solvency index. Debt to equity increased from 0.46 to 0.56, and the quick ratio declined from 2.75 to 2.47.
D
Sell
11/11/2021Upgraded
BIOLASE, Inc. (BIOL) was upgraded to D from D- on 11/11/2021 due to an increase in the solvency index.
BIOLASE, Inc. (BIOL) was upgraded to D from D- on 11/11/2021 due to an increase in the solvency index.
D
Sell
11/8/2021Downgrade
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
11/17/2020Upgraded
BIOLASE, Inc. (BIOL) was upgraded to D from D- on 11/17/2020 due to a large increase in the solvency index and valuation index. The quick ratio increased from 0.45 to 1.04, and debt to equity declined from 12.91 to 1.19.
BIOLASE, Inc. (BIOL) was upgraded to D from D- on 11/17/2020 due to a large increase in the solvency index and valuation index. The quick ratio increased from 0.45 to 1.04, and debt to equity declined from 12.91 to 1.19.
D
Sell
9/1/2020Downgrade
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 9/1/2020 due to a decline in the volatility index and total return index.
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 9/1/2020 due to a decline in the volatility index and total return index.
D
Sell
8/17/2020Upgraded
BIOLASE, Inc. (BIOL) was upgraded to D from D- on 8/17/2020 due to a large increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.26 to 0.45, earnings per share increased from -$0.1906 to -$0.1236, and EBIT increased 25.65% from -$5.35M to -$3.98M.
BIOLASE, Inc. (BIOL) was upgraded to D from D- on 8/17/2020 due to a large increase in the solvency index, growth index and volatility index. The quick ratio increased from 0.26 to 0.45, earnings per share increased from -$0.1906 to -$0.1236, and EBIT increased 25.65% from -$5.35M to -$3.98M.
D
Sell
6/11/2020Downgrade
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 6/11/2020 due to a decline in the total return index and volatility index.
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 6/11/2020 due to a decline in the total return index and volatility index.
D
Sell
5/27/2020Upgraded
BIOLASE, Inc. (BIOL) was upgraded to D from D- on 5/27/2020 due to an increase in the total return index and volatility index.
BIOLASE, Inc. (BIOL) was upgraded to D from D- on 5/27/2020 due to an increase in the total return index and volatility index.
D
Sell
5/12/2020Downgrade
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 5/12/2020 due to a large decline in the solvency index, growth index and volatility index. EBIT declined 75.59% from -$3.05M to -$5.35M, the quick ratio declined from 0.56 to 0.26, and total revenue declined 53.02% from $10.18M to $4.78M.
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 5/12/2020 due to a large decline in the solvency index, growth index and volatility index. EBIT declined 75.59% from -$3.05M to -$5.35M, the quick ratio declined from 0.56 to 0.26, and total revenue declined 53.02% from $10.18M to $4.78M.
D
Sell
5/1/2020Upgraded
BIOLASE, Inc. (BIOL) was upgraded to D from E+ on 5/1/2020 due to a major increase in the solvency index, volatility index and total return index.
BIOLASE, Inc. (BIOL) was upgraded to D from E+ on 5/1/2020 due to a major increase in the solvency index, volatility index and total return index.
E
Sell
4/6/2020Downgrade
BIOLASE, Inc. (BIOL) was downgraded to E+ from D- on 4/6/2020 due to a significant decline in the solvency index, valuation index and volatility index. Debt to equity increased from -12.98 to 36.58, and the quick ratio declined from 0.75 to 0.56.
BIOLASE, Inc. (BIOL) was downgraded to E+ from D- on 4/6/2020 due to a significant decline in the solvency index, valuation index and volatility index. Debt to equity increased from -12.98 to 36.58, and the quick ratio declined from 0.75 to 0.56.
D
Sell
11/29/2019Upgraded
BIOLASE, Inc. (BIOL) was upgraded to D- from E+ on 11/29/2019 due to an increase in the valuation index.
BIOLASE, Inc. (BIOL) was upgraded to D- from E+ on 11/29/2019 due to an increase in the valuation index.
E
Sell
11/13/2019Downgrade
BIOLASE, Inc. (BIOL) was downgraded to E+ from D- on 11/13/2019 due to a noticeable decline in the growth index, total return index and valuation index. EBIT declined 38.42% from -$3.53M to -$4.88M.
BIOLASE, Inc. (BIOL) was downgraded to E+ from D- on 11/13/2019 due to a noticeable decline in the growth index, total return index and valuation index. EBIT declined 38.42% from -$3.53M to -$4.88M.
D
Sell
9/10/2019Upgraded
BIOLASE, Inc. (BIOL) was upgraded to D- from E+ on 9/10/2019 due to an increase in the valuation index.
BIOLASE, Inc. (BIOL) was upgraded to D- from E+ on 9/10/2019 due to an increase in the valuation index.
E
Sell
8/22/2019Downgrade
BIOLASE, Inc. (BIOL) was downgraded to E+ from D- on 8/22/2019 due to a major decline in the solvency index and valuation index. Debt to equity increased from 1.67 to 3.66.
BIOLASE, Inc. (BIOL) was downgraded to E+ from D- on 8/22/2019 due to a major decline in the solvency index and valuation index. Debt to equity increased from 1.67 to 3.66.
D
Sell
5/29/2018Upgraded
BIOLASE, Inc. (BIOL) was upgraded to D- from E+ on 5/29/2018 due to an increase in the valuation index.
BIOLASE, Inc. (BIOL) was upgraded to D- from E+ on 5/29/2018 due to an increase in the valuation index.
E
Sell
5/11/2018Downgrade
BIOLASE, Inc. (BIOL) was downgraded to E+ from D- on 5/11/2018 due to a large decline in the growth index, valuation index and total return index. EBIT declined 22.96% from -$4.22M to -$5.18M, total revenue declined 20.69% from $12.63M to $10.02M, and operating cash flow declined 11.89% from -$4.26M to -$4.76M.
BIOLASE, Inc. (BIOL) was downgraded to E+ from D- on 5/11/2018 due to a large decline in the growth index, valuation index and total return index. EBIT declined 22.96% from -$4.22M to -$5.18M, total revenue declined 20.69% from $12.63M to $10.02M, and operating cash flow declined 11.89% from -$4.26M to -$4.76M.
D
Sell
3/11/2016Downgrade
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and growth index.
BIOLASE, Inc. (BIOL) was downgraded to D- from D on 3/11/2016 due to a significant decline in the total return index, volatility index and growth index.
OTC PK
03/06/2025 2:52PM Eastern
Quotes delayed
